Pharmaceuticals

Abbott (NYSE: ABT) announced today that it has expanded its Healon family of ophthalmic viscosurgical devices with the European CE Mark of Healon EndoCoat OVD.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has been advised by the U.S. Food and Drug Administration that no advisory committee meeting will be scheduled in connection with its review of the New Drug Application for CORLUX, a glucocorticoid receptor type II antagonist...

Corcept Therapeutics (NASDAQ: CORT) today announced the appointment of Gary C. Robb to the position of Chief Financial Officer, effective September 1, 2011. Mr. Robb will oversee Corcept's financial operations, including preparations for potential commercialization of our first product, business...

Abbott (NYSE: ABT) announced today it has received 510k clearance from the U.S. Food and Drug Administration for a new in vitro diagnostic test to aid in determining the prognosis of patients with chronic lymphocytic leukemia, a cancer of the lymphocytes. Abbott's Vysis CLL FISH Probe Kit is the...

Santarus, Inc. (NASDAQ: SNTS) and Depomed, Inc. (NASDAQ: DEPO) today announced that they have entered into a new commercialization agreement for GLUMETZA® (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory...

Duncan Williams maintained its Forest Laboratories (NYSE: FRX) Buy rating and $48 price target in a research report published today. In the report, Duncan Williams states, "Forest successfully thrwarted Icahn's attempts to install directors on its board and we think the experience has strengthened...

GlaxoSmithKline (NYSE: GSK) announces that in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 5th May 2011 it purchased 2,300,000 of its Ordinary shares of 25 pence each on 19 August 2011. The highest price paid per share was 1255.5 pence per share...

Shares of Forest Laboratories (NYSE: FRX) are higher on the session by 0.15%, currently trading at $24.68. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average. Options traders are focusing on puts today. A short while ago the...

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the U.S. Food & Drug Administration (FDA) has accepted the ADASUVE New Drug Application as a complete, class 2 response to the FDA's action letter, with an indicated Prescription Drug User Fee Act (PDUFA) goal date of February 4,...

Duncan Williams has published a research report on Forest Laboratories (NYSE: FRX) after the Icahn crisis. In the report, Forest Laboratories wrote, "Forest successfully thrwarted Icahn's attempts to install directors on its board and we think the experience has strengthened the company. During...

On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Sanofi-Aventis (NYSE: SNY) has a “great yield.” He advises investors to buy the stock. Cramer remains “bullish on EOG Resources (NYSE: EOG).” For Bank of Montreal (NYSE: BMO), he said, “Although I do not like U.S. banks right...

Amarin (NASDAQ: AMRN) has received a rejection letter from the U.S. Patent & Trademark Office for its drug, AMR101, which treats high levels of triglycerides, a fatty blood substance that can lead to heart problems. It is projected to be a blockbuster drug, with potential annual sales of up to...

Forest Laboratories, Inc. (NYSE: FRX) today announced that, based on the estimates of its proxy solicitor, preliminary results from its Annual Meeting indicate that shareholders have elected the Company's entire slate of director nominees by a significant margin. The Forest directors who were...

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that Michael Van Every has resigned from Valeant's Board of Directors due to health reasons.

Piper Jaffray is out with a research report on Endo Pharmaceuticals (NASDAQ: ENDP) and it has an Overweight rating and a $46 price target. In a note to clients, Piper Jaffray writes, "Yesterday, Endo announced the termination of its development program for axomadol, a potential new chemical entity...